Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lifted by Oppenheimer from to in a research report sent to investors on Wednesday, The Fly reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock.

REGN has been the topic of several other research reports. JPMorgan Chase & Co. reaffirmed a hold rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, January 14th. Zacks Investment Research raised Regeneron Pharmaceuticals from a hold rating to a buy rating and set a $360.00 price target on the stock in a research report on Monday, November 11th. BidaskClub raised Regeneron Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, January 17th. Canaccord Genuity lowered their price target on Regeneron Pharmaceuticals from $353.00 to $320.00 and set a hold rating on the stock in a research report on Wednesday, October 9th. Finally, Piper Jaffray Companies set a $435.00 price target on Regeneron Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, October 8th. Thirteen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Regeneron Pharmaceuticals has an average rating of Hold and an average price target of $390.11.

Regeneron Pharmaceuticals stock traded down $2.54 during midday trading on Wednesday, reaching $356.60. The stock had a trading volume of 716,655 shares, compared to its average volume of 543,865. The firm’s fifty day simple moving average is $375.42 and its 200-day simple moving average is $323.72. Regeneron Pharmaceuticals has a 1-year low of $271.37 and a 1-year high of $442.00. The stock has a market capitalization of $39.93 billion, a P/E ratio of 19.09, a price-to-earnings-growth ratio of 1.00 and a beta of 1.20. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.27 and a current ratio of 4.03.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $5.13 by $1.54. The firm had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.98 billion. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.87 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 20.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals declared that its Board of Directors has approved a stock buyback program on Tuesday, November 5th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the biopharmaceutical company to repurchase up to 2.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

In other news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $340.44, for a total transaction of $340,440.00. Following the completion of the transaction, the director now directly owns 10,323 shares in the company, valued at approximately $3,514,362.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neil Stahl sold 7,364 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $338.52, for a total value of $2,492,861.28. Following the completion of the sale, the executive vice president now owns 21,150 shares of the company’s stock, valued at $7,159,698. The disclosure for this sale can be found here. Insiders have sold a total of 109,543 shares of company stock valued at $40,357,770 over the last quarter. 11.84% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Nuveen Asset Management LLC boosted its stake in Regeneron Pharmaceuticals by 700.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 352,815 shares of the biopharmaceutical company’s stock valued at $110,432,000 after purchasing an additional 308,740 shares during the period. Pictet Asset Management Ltd. raised its holdings in Regeneron Pharmaceuticals by 11.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 601,284 shares of the biopharmaceutical company’s stock valued at $166,796,000 after acquiring an additional 62,926 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Regeneron Pharmaceuticals by 62.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 159,054 shares of the biopharmaceutical company’s stock valued at $44,104,000 after acquiring an additional 61,276 shares in the last quarter. State Street Corp raised its holdings in Regeneron Pharmaceuticals by 1.6% in the 3rd quarter. State Street Corp now owns 3,529,859 shares of the biopharmaceutical company’s stock valued at $979,183,000 after acquiring an additional 57,027 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in Regeneron Pharmaceuticals by 690.0% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 63,200 shares of the biopharmaceutical company’s stock valued at $17,532,000 after acquiring an additional 55,200 shares in the last quarter. Institutional investors and hedge funds own 66.43% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: What member countries make up the G-20?

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.